Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. Transcript, audio stay in one workspace.
The latest filing states the doubt was alleviated.
“As a result of continuing anticipated operating cash outflows as we commercialize our approved product in the U.S. and globally and accelerate our development efforts, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash and cash equivalents, and investments in marketable securities; sales of our approved product; capital to be raised through equity offerings, including but not limited to, the offering, issuance and sale by us of our common stock under our Form S-3ASR shelf registration statement; and our potential ability to borrow from affiliated entities will be sufficient to fund our operations through at least the next 12 months following the issuance date of the condensed consolidated financial statements based primarily upon our Founder, Executive Chairman and Global Chief Scientific and Medical Officer’s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt.”View the 10-Q filed Nov 9, 2026
Conference · 2026-11-16
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Executive readout · one minute
Read the call alongside every captured source. Transcript, audio stay in one workspace.
Research coverage
2 live sources
Switch sources without leaving this page or losing your listening position.
Open the source you need; every reader stays inside this workspace.
I'm also really excited to introduce Richard Atcock as CEO of ImmunityBio. Thank you. Thank you. I would love to just say, first of all, thank you to the UBS team for inviting us to speak here and for those in the room, but also for those listening online. Obviously, everybody is familiar with forward-looking statements on these pieces. On these, I would refer you to our website for any of these pieces if you have questions. So when you think about immunity bio, and Dr. Patrick Tsumsheng, who is the founder and really the scientific and medical visionary that has brought all of this together, the way of thinking about immunity bios, first and foremost, is that we've got a number of different platforms, our fusion proteins, our DNA vaccine vectors, and our cell therapies. Well, people talk a lot about, and today we'll talk a lot about Anctiva. I always remind people that we're not just a one drug and one indication company, and that's what separates us from many of the other companies that are out there. But if you look at our fusion proteins, you'll see, which is really Anctiva, and I always like to say it is the first. Product is approved inside of there. There's an entire pipeline of other fusion proteins that we're working through from very early stages through on that as well. But Anctiva, and we'll talk about that most today, is now approved in 35 different countries across multiple indications. So I'm going to spend most of the time today really talking about Ancteva, whereas here are IL-15, and when Dr. Soon-Sheng first brought this out, what he said is my belief and our belief is that Ancteva can become the backbone across all immunotherapy, whether it's ours or somebody else's. Now our job, obviously, that's not done. We're under trials with many of those, but it's really to prove that out, and I think we're under a very strong basis of that with the approvals that we have, Bladder cancer, now an expanded label in bladder cancer, as well as lung cancer in Saudi Arabia and the United Arab Emirates. Obviously, more work to do there. But if you look at it, IL-15 is a backbone compared to like checkpoints like Keytruda. You'll see where is Keytruda, and I'm not trying to do a head-to-head here. We've got 19 different tumor types that they set this out, and there's so far nothing we've seen that doesn't give us belief that we can have effectiveness in many of these as well. But in lymphopenia, which we know, and if you look at the approved FDA label, What it says is that it activates and proliferates CD8 killer T cells, helper T cells, memory T cells without Treg, and so really that's what lymphocytes are, is your natural killer cells and T cells, and so right inside of the FDA label, and we've had this conversation with them, is we believe they've already approved the first lymphocyte-stimulating agent on those. Now, our job is to bring that from bladder cancer across all of the other ones. But the market opportunity is quite remarkable because one in five adults suffer from this, 54 million people on those. So these are just astronomically large, large indications through those. The one that we're really excited about, and we've been working with this with Anctiva, is now in sepsis. A phase two trial has now been fully authorized. We're working with sites like Cleveland Clinic and others around the country and world to be able to set that up. Two reasons that I'll say we're really excited about sepsis is, first, no one's been able to touch it. Our early work we've done and single-patient INDs we've done have shown the exact effect we're looking for, because if you look at sepsis, what happens? You've got this hyper-inflammation phase, and then they crash. Well, what's crashing? The lymphocytes. And so, there you go. Then you know specifically. From a hospital and I ran large health systems, and part of my background ran large health insurance companies as well, sepsis is one of the most expensive treatments because nothing does. And if, unfortunately, many people die, and if they don't, it can be a very long prognosis, you know, drug out event from those. So sepsis is one, well, early. The teams that we've been working with, and again, Cleveland Clinic, when we presented this to them, they're like, this is one of the most exciting things we've seen because it impacts on all sides of this. And then our cancer vaccine, what we've been doing with the NIH on that for Lynch syndrome, one in 279, or 1.2 million Americans, all of these talk about just what is the potential size of a just very large market, but it demonstrates what is the opportunity for Anctiva to act, as Dr. Sunsheng originally said, the backbone across all immunotherapy. Now, I'm not going to go through every one of these. I like to say this. I was just in a one-on-one investor meeting, and the thing he told me is he said, you guys just keep delivering one after the other one. And I told him, I said, everything that we've said we're going to do, we're going to do. We keep checking them off. The one variable that we can't always control is time. But if we don't get the time we want, we just keep after it and keep working through those. I just addressed our team, and I'll just share this as a little side story back at ImmunityBio because we got the expanded label for papillary or full BCGN responsive, and what I told the team there was I said the thing I'm most proud about all of you is resilience. Because whenever you get something that stops in front of you, we don't stop. We just keep working our way through it. But if you look at this now going through these franchises in bladder cancer, all of these BCG unresponsive, unresponsive with papillary, they really come together to now just be a BCG unresponsive product. Our BCG naive, this one will be talking more about this as well. And then BCG alternative options from those and lung cancer. Again, moving on those lymphopenia, and then as we talked about our cancer vaccine. So let's go now into BCG on responsive space. Right out of our package insert, if you look at those, the European label is 53 months and ongoing duration. That's what makes Inctiva is so special, and you'll probably hear about it in one of the videos coming up here, is that memory T cell really separates it. Yes, you get a response. Yes, you need the natural killer cells. You need the T cells, but you need that long-term duration, and this is what separates everybody, Inctiva, from everybody else, and there's duration, duration, duration. So some of the key highlights on those, 84% of the patients who responded to Anctiva were able to maintain their bladders at 36 months. That's right out of the New England Journal of Medicine papers and Journal of Urology papers. 71% of the participants had a complete response, meaning their complete cancer was eliminated from those. 53 months of duration, as I indicated, that's right out of our European label on those 99% disease-specific overall survival at three months. These are the types of things that set this up as truly what we believe, and the labels are demonstrated, that is the best in class. We've had great success so far with our commercial launch from payers being on board and launching in all of these different countries now. Commercial sales continue to expand on all of those different pieces. Our BCG unresponsive, again, through all of this quarter we had was the smaller labels, CIS plus and minus papillary. Now we've just received in the last couple of weeks even the label expansion on that. Here is just another look at this and trying to take a look at it in units you'll see on those. So that's our BCG unresponsive space, and I'll share this story with you as we got our approval, and there was many people who didn't think we were going to get it. I had, sincerely, over probably the two or three days afterwards, 20-plus doctors called me and said, congratulations. Almost. All of them said the same thing. Finally, we can now just get back to treating patients the way we used to. Because we didn't used to have this nomenclature of cis plus and minus and papillary only and all of this. They were just BCG unresponsive patients. They were high risk patients. Now Anctiva is the only one that has full FDA labels to be able to treat that BCG unresponsive patient like that. And we believe that will separate you as well again. Now, in the naive space, and this is very important because we've finished and we've submitted this out there, our BCG naive trial. The Independent Data Monitoring Safety Committee has met and said you don't have to continue to expand that trial, and we just reported out in the last days. That we had met the endpoint to our BCG naive trial. We'll be talking more about that in the middle. But as you can see, this is a very large indication as well, giving us much more on those. So getting that first approval, then the label expansion, and now submitting and moving forward to that in the naive setting even continues the story more. So, in BCG, our Anctiva plus BCG in the naive setting, we've demonstrated this with the earliest phase one patients. They're now out nine plus years. There was originally nine patients inside of theirs when we were getting our unresponsive first indication label. The FDA called and said, we'd like to know where those patients are. We had to smile and say, you mean the patients that we were authorized to track for two years? You'd like to know where they're at eight plus years later? And they smiled and said, yeah, and if you could do it by Tuesday, that'd be great. Somewhat not joking. Fortunately, they were all at one center. We called that center right away. They were fantastic. They said, we'll open an IRB for you tonight. You guys can come. We'll give you all access to all the data. And we were able to identify six of six. Two had passed of diseases other than bladder cancer. One was unidentifiable because no one was supposed to be tracking. But six of six patients, all six of those were still in complete response nine and a half years later. All of them had not had another treatment. And most importantly, all of them still had their bladders intact. That is really remarkable. And that's the power of the duration that we're really excited about on those. So the conclusion on that one is Anctiva plus BCG in the nine in those patients is a durable, complete response. And it's not just a complete response, but a durable, complete response.
When we began the clinical trial of N803 plus BCG back in 2014, we had the inclination that this could be a game-changer. The very first patient we enrolled was Elvera. She's an interesting patient because she has a history of multiple cancers.
It started with my breast cancer, and then after the left kidney cancer, so I only have one kidney right now. Thank you. And then the thyroid. I said, no, I don't have thyroid. So I was thinking we might probably gonna take out my brother.
We saw no dose-limiting toxicity, so the patients did extremely well. In 803, it increases the proliferation of T-cells. It increases NK cells and increases memory T-cells as well. And the memory T-cells are important because they lead to a long duration of complete remission, and that's what we didn't know back then when we were developing this clinical trial. We were just blown away with the effect that we've seen.
Unless COVID-19. I still can do all the things that I want to do. I'm enjoying life. I'm not even concerned about it on a daily basis.
Finally, Dr. Teeth, he says, I don't think it's going to come back because I think you're in full remission.
Feels good.
Over 20 years of practicing urology, I have not seen a clinical trial with this durability, so I'm really interested to see how this plays out.
I think that's the key there, is it really is. Obviously, you want a response, because if you don't have a response, it doesn't matter. But you want a duration of that response. And that's what's exciting about this and why we're really excited to be able to see this data. So this is what we're bringing forward. The full accrual was achieved in February or end of February. From that, we completed everything out. We have met the endpoint. We announced that. And most importantly, the p-value was 0.01. And so we know that we've got something that's statistically significant when you're that tight in all of those pieces. We are on track, as Dr. Soon-Sheng and myself said earlier in the year, that our intent was to submit it, the BLA or the SBLA, by the end of this year. And I'm happy to report today that we're completely on track with that. The teams have been working. It's incredibly hard, and we'll put the final touches on it in the coming weeks and then submit that out. But again, that statistically significance of P01 gives us a lot of confidence on what Okay, so I want to transition now and talk a little bit about BCG. We've got, as you likely know, we have two different options that we're working with on those. There's been a 15-year BCG shortage, and when your drug is paired with BCG, obviously that's important that you solve this, bring that inside of your control. The first one is Tokyo strain. This was just announced, the readout of this trial was just announced at ASCO-GU just this year. Right after that readout, and we'll be talking about that now. So myself and Dr. Sun-Sheng flew right to Japan, and we licensed this out so that we could go ahead and bring this forward to the market. Our teams, it's been on the market for three or four decades in Japan. It was a thousand patient clinical trial that was run in the United States by NIH and SWOG, all the large academic centers, and it basically read out as the same as you can see here, Tokyo versus TICE. And so that's really what we wanted. The hazard ratio, you can see there. This is really exciting because we think this is one of the best ways to be able to bring a real authorized second strain back to the U.S. market. But not to only have one, because the United States should have more than one. In Europe, they actually have six strains approved. We've had one for the last 15 years, and it's been under shortage. We actually, right after getting this approval, brought forward the Serum Institutes. And the Serum Institute, if you don't know, is the world's largest BCG manufacturer, their recombinant strain. We've worked with the FDA. The FDA asked us, would you please do this under an expanded access right away? We think that's the fastest way. We make a determination how to bring this forward on those, and I'm happy to say that we have many, many sites all around the country that are using this, and we've delivered thousands of doses on that. So that's really the bladder franchise conversation right now. I'm going to move on to lung. So ASCO of 2025, or 2024, excuse me, was the paper that was presented there, and basically they said, uh-oh, checkpoints work and then checkpoints fail.
And nothing we're doing seems to be impacting that.
All the trials that are trying to do post-checkpoint failure aren't working, and we're left with just chemo again. And it's bad, and the patients don't have good outcomes. What are we going to do? This was the challenge that was facing all of those. As many of you know, we've brought forward many trials that are on those, QUILT3055 probably being the most prevalent trial on that one. I think what's important when you look at those is in lung cancer specifically, all trials have shown that your chemo arm is going to be somewhere in that 8 to 10 months, less than 10 months. Instance EN, their recommendation is to not re-induce checkpoint after checkpoint failure because there's nothing, it's not going to have a connector be able to reconnect on that. Well, QUILT3055, as I said, in this trial is a second and third line non-small cell lung cancer trial, and you can see from the data here that we're showing when you have an ALC responder, 21 months. Versus the 8 to 10 months on some of those pieces. Here, the ALC non-responders at 11 and a half, the overall one was about 14.6 through those. And so, really exciting data. That led us to then bring forward our Rescue 201A.
When I found out that I had cancer, lung cancer. For two and a half years, my standard of care, it worked. I got to ring the bell. I was like, it's done, you know, but unfortunately it wasn't done. Mid-June 2022, I went and got a CT scan. I was alone and I got my results that are stage four. Because I had like 24 tumors in my body. My left and right lung on my thyroid and on the rib. So this opened up a chance for me to get into a clinical trial and do something different. My doctor suggested the same chemotherapy that they worked before, and to go on to K-Truda, as well as an N803. At that point, I was really, really sick. I wasn't able to walk. I couldn't breathe. I had to sit up to sleep at night. My doctor had said, you have six to eight weeks to live if we don't do this. I didn't hear that. We started At the end of August 2022, it was every three weeks. My first CT scan was October 25th. So Dr. Luke, he was blown away because it was 75 to 80% improved in just two months. They called me as a miracle patient. He said, I have never seen anything like this. Okay, then let's just keep going. Let's do this. My faith was always stronger than my fear. But it's a tough thing to go through. Chemotherapy is just killing everything. After treatment, I would be in bed for a week. The positive thing was I was with my granddaughter.
Hi.
Good to see you. Good to see you, too. She woke me up every morning to show me what she was wearing to school. Right at the end of 2022, I just said, I can't do this anymore. We need to stop the chemotherapy. In January of 2023, when I had the first treatment, when I just had the K2 and the N803, I was able to eat. I wasn't weak. So the quality of life was so much better with just the two, the N803 and the K2. It's almost like I immediately felt better. And my scans were improving and improving. I started walking. I joined the gym, enjoying my granddaughter. That fall, I ran the whole Harvest Festival. So it was, you know, I was able to do life again. It's all good news. It's all been positive. So I'm still getting that every three weeks. My last scan that I had, it showed that there's not any tumors in my right lung. It's my left lung, but the ones in my left lung have shrunk. My thyroid is gone. It's helped me to really want to live life. It's a miracle. To go from six to eight weeks to live three and a half years ago, to still be here.
As I said on that one, the data that we brought forward on that, Saudi Arabia was able to approve that. They were the first in the world to be able to approve that for lung cancer. Right on the heels of that, the United Arab Emirates called us and said, please submit this to us as well. They've now approved it. I can tell you that we have other health authorities that are asking us to do the same. We're still working with them on those. I don't have any announcements today. It's really exciting data. As I said before, that we... Clicked into that.
It was really that QUILT 3055 trial that is the basis for all of those pieces.
So right here, again, we're talking about the world's first approval for an immunotherapy, 2.0, and non-small cell lung cancer, which has given you, again, that activation of natural killer and T cells. We believe this. We were incredibly excited because it was more of that proof principle of what Dr. Sunsheng's original hypothesis was that we think Anctiva can become that backbone across all immunotherapy. And this is now the second approval in another area. So now we're going to talk a little bit about what we've been doing in solid tumors here in the last few minutes. So standard of care as we sit here today. And often this happens. In many instances, it's exactly wrong. And what it's doing is it's actually destroying the very cells that the body needs to fight the cancer. It goes in there, and many times it's chemo, acts like a bomb, blows up everything, the bad, but you also remove the good that you need to be able to fight that, and so you're left with nothing on those. You have a low lymphopenia count. We can see this in trial after trial, indication after indication when we go to those. When you have a low ALC count, it's absolutely correlated. There's been all kinds of scientific papers from us and others that show you have an overall that reduces your overall survival, which is exactly opposite of what you want to have. So this is a paper that was done in 2019, not by us, demonstrating this. This is a longstanding recognition of the impact of your global lymphopenia, again, your NK and your T cells, on the relapse of survival for overall survival patients with solid tumors across all tumor types. It's agnostic. If you have low ILC, your absolute lymphocyte count, you're going to have this, and it goes over and over again across all of these. Quilt 2023, which was a trial that that lady that we just saw in the video was actually in, is a randomized clinical trial in Frontline, which is. Anctiva or N803 plus checkpoint. And I say Anctiva on that one because it's approved in two indications. It's N803 when it's in the unapproved one. So I want to make that clarification on those. It's not approved in the United States yet, and we're working on that one. We've moved forward in the second line setting, and that is the Rescue 201A trial on those. But here you see this very strong, again, p-value 0.0065 and the clear separation, as you would expect. So let's talk a little bit about your ALC and what does it mean to introduce this. So, on the left side, if you have low red blood cells, what do you do? You get epigen. If you've got low neutrophil, what do you do? Neupogen. There's been nothing, though, and while it's very important that you have epigen and neupogen available, those are both induced by the treatments. Whatever type of treatment you're getting is causing those to go down. Ultimately, and that same treatment is causing the reduction in many instances of your lymphocytes. There hasn't been anything, and we're not here saying that it's done, but that treatment has been missing for the last 50 years. Well, we believe ultimately, and this is what we have to prove out, and this is what we're doing through trials and through expanded access, that Ankiva can do that. It was, as it said on the bottom there, it was opened as an expanded access with the FDA in
2024 for that exact indication, though. So it is authorized in that one.
Here again is another paper, Excess Mortality. This one is really... I'll say impressive, but startling maybe is a better word from it. And the question they ask is, are low lymphocyte levels associated with the reduction of survival? And then you go right into the findings is that lymphocytes were directly associated with the shortened survival, independent clinical variables, and the risk is further highlighted when you have this, again, low lymphocyte count. And so it's paper after paper that is demonstrating the proof of these pieces. This, again, is from that same JAMA paper, shows you an increased mortality in all causes. Now, here's your increased mortality on the right side in cancer. So, the stage is set across each one of these, and that's part of, as we've said, what we're trying to do is walk through this very methodically. Now, I want to talk to you in the last couple of minutes about sepsis. So... Right now, sepsis is not treated as an immune disorder, and that's not the way people even think about it, and when we were sitting down with the folks from multiple academic institutions, and specifically Dr. Sunsheng and myself were at Cleveland Clinic, and he presented this to some of the world's leading scientists and clinicians, and he said, I think we need to think of it this way, you could actually hear almost this excitement in the room, because they're like, Oh, my God, maybe we've been doing it exactly wrong, and now we need to flip it on its heels and actually treat sepsis like it is an immune paralysis that is happening on these pieces. As we go through here, this is the trial that has now been opened. It's a phase two. This is a blinded randomized control trial, and as I said, it's been fully authorized by the FDA. We're just in the initial stages of getting sites like Cleveland Clinic and others associated with it. We have global sites from around the world that will be doing this, and we believe what is so, I don't want to say exciting, what is positive in sepsis is it's a very short timeframe, whereas in lung, overall survival is going to be measured in a couple of years, and sepsis is a 28-day test, and so it gives you a much faster approach to be able to navigate through these pieces. I don't want to say it's exciting because 28 days is not good for those unfortunate sepsis patients, the few that don't make it on those. And as we close out here, I want to just talk about Lynch syndrome. So Lynch syndrome, again, this was a study. Lynch syndrome, for those of you who don't know, is a genetic malformation. When you actually have this inherited disorder, you have a much higher propensity to get diseases like colon cancer on those. So the NIH and NCI, independent of immunity bio, did their own study on this and said, we have an increase in colon cancer. What is causing this? One of the pieces they found was this increase in Lynch syndrome, and it impacts just literally millions of people globally on this one. So independent of immunity bio, they said, we need to scour the world and figure out what is the right treatment. Lo and behold, we get a phone call and they said, Dr. Suncheng, we've been doing this. We think Anctiva plus what you call your triad is the right approach. So now this is our Anctiva, or N803, in combination with our ADD5 vaccine on those. That trial was fully run, fully paid for by the NIH, and run across all of these amazing institutions. It is fully done. They will be reading out in 2027 on that one, so we look forward to that. We've seen some of the early data on those, and we're seeing the increased lymphocytes, exactly what you would expect on those, and so we look forward to this. In the last minute, I just really want to close with this. In summary, if you look at this, what our objective, and I said this from the very beginning, our purpose is to find what is that next blockbuster? What is that that is going to take immunotherapy beyond checkpoints, or as Dr. Sunsheng has called it, immunotherapy 2.0. And our job is to be able to demonstrate and prove this. But it's not just us who are saying this. Dr. Cheever put this out in 2008. These are his words, not ours. They brought together a group of scientific people from around the world at NIH and others, and they had all of them, ACR, everybody there, and they asked them to rank what do they think, and this was in 2008, what are all of the top-rated drugs. The number two drug they came up with was an anti-PD-1. We all know that became Keytruda. But the number one drug that they identified was IL-15. If you read it, it actually specifically says an IL-15 with a receptor alpha presentation of it would even be better on those. Well, that's specifically what Anctiva is. They called it a T-cell growth factor, which is one of the things we now know right out of our labels, that it activates and proliferates T-cells and NK cells. That's what we've been doing, and that's what Dr. Soon-Sheng and the entire team have set forward. As we walk through those, to put it in perspective, this is what Keytruda became out of that through all of those. They've got 19 different tumor types. I'm not saying it's a one-to-one. I want you to understand what the market opportunity is and the way we've been trying to approach this, and that's what Immunity Bio is working on now. And again, in these last slides here, if you look at these, all of these tell you about, because there's a patent cliff coming up on site of these. And so the opportunity here is for Anctiva Plus checkpoint. We actually have patents that go out to 2035 and even 2037 on some of those. So finding that next blockbuster is really the work we've been at and the work that we now have done approved. And again, UAE and Saudi Arabia, as well as 35 other countries, is demonstrating where we can see this on a global basis. So, summary on this one here, aisle 15, as we talked about at the very beginning, you've got an opportunity across multiple tumor types, across lymphopenia, hopefully, across sepsis is what we're trying to prove out right now, but also as a prevention of cancer. Obviously, we have our current approvals, and this is the work we have to do, and I'll leave it right there with the ISI information.
And I think with that, we're out of time unless there's any questions that we need to take. Okay. All right. Thank you all very much. Appreciate it.